Researchers in the UK are hoping to develop a rapid, saliva-based test that could identify stroke patients who need rapid treatment to prevent irreversible brain damage.
Swiss biotech Idorsia has suffered a setback in its bid to develop clazosentan for a form of stroke in the west, despite winning approval of the drug in Japan last year.
A partnership between two UK digital health companies – Brainomix and Visionable – aims to overcome bottlenecks that hold up the care of patients in the critical time period following a str